Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Non-Current Deferred Tax Liability (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Non-Current Deferred Tax Liability for 5 consecutive years, with $425527.0 as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Deferred Tax Liability fell 49.52% to $425527.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $425527.0, a 49.52% decrease, with the full-year FY2025 number at $495113.0, changed N/A from a year prior.
  • Non-Current Deferred Tax Liability was $425527.0 for Q4 2025 at Neuphoria Therapeutics, down from $460320.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.3 million in Q2 2022 to a low of $425527.0 in Q4 2025.
  • A 4-year average of $776452.9 and a median of $796530.5 in 2024 define the central range for Non-Current Deferred Tax Liability.
  • Peak YoY movement for Non-Current Deferred Tax Liability: fell 14.12% in 2023, then tumbled 49.52% in 2025.
  • Neuphoria Therapeutics' Non-Current Deferred Tax Liability stood at $1.3 million in 2022, then decreased by 14.12% to $1.1 million in 2023, then dropped by 23.81% to $842921.0 in 2024, then crashed by 49.52% to $425527.0 in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Non-Current Deferred Tax Liability are $425527.0 (Q4 2025), $460320.0 (Q3 2025), and $495113.0 (Q2 2025).